Analysts hold mixed views on Karyopharm Therapeutics due to its slower growth compared to the industry and increased loss per share estimates for next year, leading to a lower future valuation estimate.
Investors' belief in Karyopharm Therapeutics' poor revenue performance and underwhelming outlook contribute to its low P/S ratio. These conditions form a barrier for the share price.
$Karyopharm Therapeutics(KPTI.US)$Watching Karyopharm Therapeutics; Traders Circulate Analyst Comments Suggesting "With The MOR Takeover Interest, A Larger Cancer Company Could Also Be Interested In Acquiring KPTI For Selinexor"
$Karyopharm Therapeutics(KPTI.US)$Presentation Of Updated Long-term Safety, Efficacy Data From A Pre-specified Exploratory Subgroup Analysis Of SIENDO Study In Patients With Advanced Or Recurrent TP53 Wild-type Endometrial Cancer
Karyopharm Therapeutics股票討論區
Hmm?
Hope this means no dilution soon?
Update
暫無評論